Adverse impact of hyperferritinemia and transfusion dependency on treatment success in myelodysplastic syndrome

Cakar M. K. , YEGİN Z. A. , Baysal N. A. , Altindal S., Pamukcuoglu M., ÇELİK B., ...More

TRANSFUSION AND APHERESIS SCIENCE, vol.48, no.3, pp.397-401, 2013 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 48 Issue: 3
  • Publication Date: 2013
  • Doi Number: 10.1016/j.transci.2013.04.025
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.397-401
  • Keywords: Myelodysplastic syndrome, Ferritin, Transfusion, Prognosis, Treatment, QUALITY-OF-LIFE, SERUM FERRITIN, MYELOID NEOPLASMS, IRON OVERLOAD, MDS, PROGNOSIS, DIAGNOSIS, ANEMIA


Background: Myelodysplastic syndrome (MDS) is characterized by peripheral cytopenias and dysplasia in one or more cell lines in the bone marrow. A significant proportion of patients require blood product support due to symptomatic anemia and/or thrombocytopenia during the course of their disease. This retrospective study was planned to evaluate the transfusion requirement of MDS patients and the role of ferritin in predicting transfusion requirement and response to treatment.